

ARISTECH

RECEIVED
APR 30 1996

96 APR 30 AM 7:54

Aristech Chemical Corporation
600 Grant Street
Pittsburgh, PA 15219-2704
412/433-2747
Telex: 6503608865
Answer Back: 6503608865MCI UW

ORIGINAL

(E)

April 23, 1996

Document Processing Center
OPPT (7407)
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460
ATTN: 8(e) Coordinator

Contains No CBI

88 940000 325

8EHQ 0794 1308

Re: Aristech Submission 8EHQ 0794-13083
Preliminary Results of the Oncogenicity Study in Mice with
Di (isononyl) phthalate

Dear Sir or Madam:

In accordance with the Toxic Substances Control Act, Aristech Chemical Corporation of Pittsburgh, Pa. is submitting follow-up data adding to previously reported information regarding the 2-year dietary testing of Di (isononyl) phthalate (DINP) in mice. Although we do not believe this information reasonably supports the conclusion of a substantial risk to human health or the environment, this information appears to meet reporting criteria established by the Agency.

In April, 1995, we reported ~~preliminary results~~ of gross pathology that suggested a ~~possible dose-related increase in liver masses in both male and female mice~~. We recently obtained ~~unaudited histopathology results~~ on these findings, together with the terminal sacrifice results. Pertinent findings of the analysis are summarized below;

~~DINP was administered to male and female B6C3F1 mice in the diet for at least 104 weeks, at the following dose levels: Group 1, 0 ppm; Group 2, 500 ppm; Group 3, 1500 ppm; Group 4, 4000 ppm; Group 5, 8000 ppm; Group 6, 8000 ppm - Recovery.~~

~~The recovery group, Group 6, received DINP in the diet for the first 78 weeks of the study, and then received the control diet for the remainder of the study period.~~



8146-94-13083
SP084 84/38/96

RECEIVED
7/11/96

RECEIVED
UNIT NHC
APR 21 AM 9:04



89960800124




The table below contains the preliminary findings from the histopathology:

Test Group	1	2	3	4	5	6
Neoplasms Male, % Total of Adenoma & Carcinoma	23	22	30	47	44	38
Female, % Total of Adenoma & Carcinoma	4	8	17	18	46	36

Once we receive a study report, we will forward a complete copy to the Agency.

If you have any questions regarding this matter, please contact me.

Sincerely,



John R. Bankston II
Supervisor,
Product Regulation
(412) 433-7686

cc: J. J. Pottmeyer III
J. A. Santory